Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis (RRP), a rare ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

The 9th MASH Drug Development Summit is the essential forum for pharmaceutical giants and innovative biotechs dedicated to ...

Following the first-ever FDA approval of a TIL therapy in the U.S., and with regulatory decisions pending in Canada and ...

In another sign of increased regulatory scrutiny of vaccines in the US, Health and Human Services (HHS) Secretary Robert F ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...